Mental state · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effect: any ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Adverse effects: use of antiparkinsonism drugs · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes adverse effects: use of antiparkinsonism drugs compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Leaving the study early · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
It is very uncertain whether switch to another antipsychotic changes acceptability of the treatment: leaving the study early compared with antipsychotic cessation (very low certainty).
1 finding from 1 review
Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Tardive dyskinesia: No clinically important improvement · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
Switch to another antipsychotic may leads to lower tardive dyskinesia: no clinically important improvement compared with antipsychotic cessation (low certainty).
1 finding from 1 review
Tardive dyskinesia: Deterioration of symptoms ‐ not reported · psychiatric patients (schizophrenia) with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Depressive symptoms · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in depressive symptoms (HAM‐D) Scale from: 0 to 54 (worse) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Leaving the study early · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in dropouts compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Response (> 50% improvement on 29‐item HAM‐D SIGH‐SAD) · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in response (≥ 50% improvement in HAM‐D score) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Remission (HAM‐D total score ≤ 8) · treatment‐resistant depression in adults
Switching to mianserin (60 mg/d) showed no clear difference in remission (HAM‐D total score ≤ 8) compared with continuing on current antidepressant (fluoxetine 20 mg/d) (low certainty).
1 finding from 1 review
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Effect on later sexual function · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Sexual function: Subjective assessment (prolactin levels, ng/ml) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Leaving the study early · patients with sexual dysfunction due to antipsychotic drug therapy
It is very uncertain whether SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE changes leaving the study early compared with MAINTENANCE RISPERIDONE (very low certainty).
1 finding from 1 review
Quality of life not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Psychopathology (PANSS) · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review
Adverse effect: extrapyramidal symptoms ‐ not reported · patients with sexual dysfunction due to antipsychotic drug therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Effect on later sexual function · patients with sexual dysfunction due to antipsychotic drug therapy
1 finding from 1 review